These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6894470)

  • 1. The duodenal mucosa in patients with renal failure: response to 1,25(OH)2D3.
    Goldstein DA; Horowitz RE; Petit S; Haldimann B; Massry SG
    Kidney Int; 1981 Feb; 19(2):324-31. PubMed ID: 6894470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of 1,25(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients.
    Goldstein DA; Malluche HH; Massry SG
    Contrib Nephrol; 1980; 18():42-54. PubMed ID: 7353379
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of 1,25-dihydroxycholecalciferol on the duodenal villi and alkaline phosphatase in the developing chick embryo.
    Moriuchi S; Yoshizawa S; Mizuno K; Hosoya N; Noda S; Kubota K
    Contrib Nephrol; 1980; 22():9-17. PubMed ID: 6893176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intestinal absorption of Ca47 in chronic renal insufficiency before and after treatment with 1,25 dihydroxycholecalciferol].
    Vattimo A
    Minerva Med; 1979 Dec; 70(54):3705-7. PubMed ID: 523001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dihydroxylated metabolites of vitamin D3 on calcium absorption in uraemic man.
    Muirhead N; Catto GR; Gvozdanovic S; Gvozdanovic D; Edward N
    Clin Sci (Lond); 1981 Dec; 61(6):723-7. PubMed ID: 6975197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.
    Brickman AS; Coburn JW; Friedman GR; Okamura WH; Massry SG; Norman AW
    J Clin Invest; 1976 Jun; 57(6):1540-7. PubMed ID: 932193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc metabolism in patients with chronic renal failure during treatment with 1.25-dihydroxycholecalciferol: a controlled therapeutic trial.
    Kiilerich S; Christiansen C; Christensen MS; Naestoft J
    Clin Nephrol; 1981 Jan; 15(1):23-7. PubMed ID: 7214749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The action of 1,25 (OH)2D3 on turnover kinetic, remodelling surfaces and structure of trabecular bone in chronic renal failure.
    Delling G; Lühmann H; Bulla M; Fuchs C; Henning HV; Jansen JL; Kohnle W; Schulz W
    Contrib Nephrol; 1980; 18():105-21. PubMed ID: 7353369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL; Felsenfeld AJ; Llach F
    Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-term therapy with calcitriol in patients with moderate renal failure.
    Healy MD; Malluche HH; Goldstein DA; Singer FR; Massry SG
    Arch Intern Med; 1980 Aug; 140(8):1030-3. PubMed ID: 6893118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcitriol in dialysis patients.
    Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC
    Clin Pharmacol Ther; 1978 May; 23(5):515-9. PubMed ID: 205382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminoaciduria in chronic renal failure--its relationship to vitamin D and parathyroid status.
    Phillips ME; Havard J; Otterud B
    Am J Clin Nutr; 1980 Jul; 33(7):1541-5. PubMed ID: 6893104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic effect of 1,24(R)(OH)2D3 versus 1,25(OH)2D3 administration in chronic renal failure.
    Coen G; Bondatti F; Donato G; Mazzaferro S; Pasquali M; Rosini S; Sardella D; Taggi F
    J Steroid Biochem Mol Biol; 1992 Sep; 42(8):823-9. PubMed ID: 1525043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol.
    Christiansen C; Rødbro P; Christensen MS; Hartnack B; Transbøl I
    Lancet; 1978 Sep; 2(8092 Pt 1):700-3. PubMed ID: 80633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of ornithine decarboxylase activity induced by 1 alpha,25-dihydroxyvitamin D3 in chick duodenal villus mucosa.
    Takahashi N; Shinki T; Kawate N; Samejima K; Nishii Y; Suda T
    Endocrinology; 1982 Nov; 111(5):1539-45. PubMed ID: 6897034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.